Clinical applications and perspectives of circulating tumor DNA in gastric cancer
- PMID: 38184573
- PMCID: PMC10770949
- DOI: 10.1186/s12935-024-03209-4
Clinical applications and perspectives of circulating tumor DNA in gastric cancer
Abstract
Gastric cancer remains a leading cause of cancer-related death worldwide, largely due to inadequate screening methods, late diagnosis, and limited treatment options. Liquid biopsy has emerged as a promising non-invasive approach for cancer screening and prognosis by detecting circulating tumor components like circulating tumor DNA (ctDNA) in the blood. Numerous gastric cancer-specific ctDNA biomarkers have now been identified. CtDNA analysis provides insight into genetic and epigenetic alterations in tumors, holding promise for predicting treatment response and prognosis in gastric cancer patients. This review summarizes current research on ctDNA biology and detection technologies, while highlighting clinical applications of ctDNA for gastric cancer diagnosis, prognosis, and guiding treatment decisions. Current challenges and future perspectives for ctDNA analysis are also discussed.
Keywords: Biomarker; Circulating tumor DNA; Gastric cancer; Liquid biopsy.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.Front Oncol. 2021 Nov 18;11:763790. doi: 10.3389/fonc.2021.763790. eCollection 2021. Front Oncol. 2021. PMID: 34868984 Free PMC article. Review.
-
Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.MedComm (2020). 2024 Nov 9;5(11):e766. doi: 10.1002/mco2.766. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39525954 Free PMC article. Review.
-
[Progress of circulating tumor DNA methylation for gastric cancer screening and management].Zhonghua Wei Chang Wai Ke Za Zhi. 2024 May 25;27(5):535-544. doi: 10.3760/cma.j.cn441530-20230710-00001. Zhonghua Wei Chang Wai Ke Za Zhi. 2024. PMID: 38778696 Review. Chinese.
-
Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.Oncotarget. 2017 Sep 1;8(43):75742-75755. doi: 10.18632/oncotarget.20608. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088906 Free PMC article. Review.
-
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).Micromachines (Basel). 2018 Feb 28;9(3):100. doi: 10.3390/mi9030100. Micromachines (Basel). 2018. PMID: 30424034 Free PMC article. Review.
Cited by
-
Preoperative Radiotherapy in Patients with Gastric and Gastro-Oesophageal Cancer: A Systematic Review and Meta-analysis.J Gastrointest Cancer. 2025 Mar 24;56(1):84. doi: 10.1007/s12029-025-01204-0. J Gastrointest Cancer. 2025. PMID: 40123010
-
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.Int J Mol Sci. 2024 Mar 30;25(7):3876. doi: 10.3390/ijms25073876. Int J Mol Sci. 2024. PMID: 38612688 Free PMC article. Review.
-
Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study.Ann Surg Oncol. 2025 Sep;32(9):6838-6850. doi: 10.1245/s10434-025-17601-5. Epub 2025 Jun 14. Ann Surg Oncol. 2025. PMID: 40517199
-
Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.Cancers (Basel). 2024 Jul 29;16(15):2692. doi: 10.3390/cancers16152692. Cancers (Basel). 2024. PMID: 39123420 Free PMC article. Review.
-
Circulating biomarkers for diagnosis and response to therapies in cancer patients.Int Rev Cell Mol Biol. 2025;391:1-41. doi: 10.1016/bs.ircmb.2024.08.007. Epub 2024 Sep 5. Int Rev Cell Mol Biol. 2025. PMID: 39939074 Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources